Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities

被引：0

作者：

Vaccaro, Marcello ^{[1
]}

Polito, Giacomo ^{[1
]}

Bagaglini, Gabriele ^{[2
]}

Capuozzo, Maurizio ^{[3
]}

Langella, Roberto ^{[4
]}

Nava, Eduardo ^{[5
]}

Zovi, Andrea ^{[6
]}

Ferrara, Francesco ^{[3
,5
]}

机构：

[1] Policlin Umberto 1, Pharm Dept, Pharm Unit, Rome, Italy

[2] ASL Latina, Pharm Unit, Latina, Italy

[3] ASL Napoli 3 Sud, Pharmaceut Dept, Naples, Italy

[4] Italian Soc Hosp Pharm SIFO, SIFO Secretariat Lombardy Reg, Milan, Italy

[5] Asl Napoli 3 Sud, Naples, Italy

[6] Univ Camerino, Sch Pharm, Via St Agostino 1, I-62032 Camerino, Italy

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2025年

关键词：

Biological drugs; biosimilars; biotechnological; healthcare system; sustainability;

D O I：

10.1080/14737167.2025.2465445

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

BackgroundBiosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.Research design and methodsA study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.ResultsThe analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.ConclusionsA comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.

引用

页数：7